News BioVaxys Technology Corp. OTC Markets

Equities

BVAXF

CA09076M1014

Delayed OTC Markets Other stock markets 17:11:04 16/07/2024 BST			5-day change	1st Jan Change
0.0357 ^USD	-31.21%		-32.00%	-12.93%

07-10	BioVaxys Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	CI
07-10	BioVaxys Technology Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Canadian Investment Regulatory Organization Trade Resumption - BIOV	03:21pm	AQ
BioVaxys Technology Corp. Announces Revocation of Cease Trade Order	07-12	AQ
BioVaxys Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	07-10	CI
BioVaxys Technology Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	07-10	CI
BioVaxys Technology Corp. Reports Earnings Results for the Full Year Ended October 31, 2023	07-09	CI
BioVaxys Technology Corp. Announces Failure to File Cease Trade Order	05-16	AQ
CSE Bulletin: Suspension - BioVaxys Technology Corp. (BIOV)	05-16	NE
Canadian Investment Regulatory Organization Trading Halt - BIOV	05-16	AQ
BioVaxys Technology Corp. Closes SECOND Tranche of Private Placement	05-10	AQ
BioVaxys Technology Corp. Closes First Tranche of Private Placement	05-03	AQ
Biovaxys Technology Corp. Delays to File Its Interim Financial Statements for the Three Months Ended January 31, 2024	05-02	CI
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	05-02	AQ
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050	05-01	AQ
BioVaxys Technology Corp. Appoints Christopher Cherry as Chief Financial Officer	04-30	CI
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	04-18	AQ
Biovaxys and SpayVac-For-Wildlife, Inc. Announce Launch of Field Trial for Large-Scale Immunocontraception in the Commercial Aquatic Farming Industry	04-10	CI
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY	04-10	AQ
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	04-05	AQ
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMage	04-03	CI
BioVaxys Technology Plans Private Placement; Down 5.9%	03-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioVaxys Technology Corp. OTC Markets

Equities

BVAXF

CA09076M1014

Summary

Filters